Rapid Micro Biosystems, Inc.
RPID- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001380106
No open-market purchases or sales by Rapid Micro Biosystems, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $30.3M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Rapid Micro Biosystems, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −2 vs. Q1 2024
- Shares held
- 18.5M
- −542.5K (−2.8%) vs. Q1 2024
- Total value
- $12.2M
- −$6.03M (−33.0%) vs. Q1 2024
- New holders
- 1
- 5 more added
- Sold out
- 3
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RPID on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $30.3M |
| Q1 2026 | 46 | $36.0M |
| Q4 2025 | 42 | $42.5M |
| Q3 2025 | 29 | $49.5M |
| Q2 2025 | 29 | $52.3M |
| Q1 2025 | 28 | $40.4M |
| Q4 2024 | 19 | $10.8M |
| Q3 2024 | 19 | $15.6M |
| Q2 2024 | 21 | $12.2M |
| Q1 2024 | 23 | $18.2M |
| Q4 2023 | 26 | $14.9M |
| Q3 2023 | 23 | $23.2M |
| Q2 2023 | 24 | $21.9M |
| Q1 2023 | 31 | $29.9M |
| Q4 2022 | 42 | $27.7M |
| Q3 2022 | 53 | $82.8M |
| Q2 2022 | 52 | $112.2M |
| Q1 2022 | 59 | $181.0M |
| Q4 2021 | 55 | $227.9M |
| Q3 2021 | 49 | $401.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Rapid Micro Biosystems, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Resources Management Corp | 500 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 442 | $0 | 0.00% | +382+636.7% | Added |
| Qube Research & Technologies Ltd | 4 | $2 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 98 | $65 | 0.00% | −148−60.2% | Reduced |
| Bank of America Corp | 164 | $108 | 0.00% | +81+97.6% | Added |
| Tower Research Capital LLC (TRC) | 8,296 | $5.47K | 0.00% | +2,749+49.6% | Added |
| Morgan Stanley | 10,108 | $6.67K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 10,974 | $7.24K | 0.00% | +10,974 | New |
| Northern Trust Corp | 15,550 | $10.3K | 0.00% | −100−0.6% | Reduced |
| State Street Corp | 26,074 | $17.2K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 58,989 | $38.9K | 0.00% | −7,198−10.9% | Reduced |
| Renaissance Technologies LLC | 65,987 | $43.6K | 0.00% | +8,600+15.0% | Added |
| Geode Capital Management, LLC | 170,572 | $112.6K | 0.00% | +9,419+5.8% | Added |
| JPMorgan Chase & Co | 573,928 | $378.8K | 0.00% | −48,903−7.9% | Reduced |
| Advent International Corp | 577,777 | $381.3K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 648,519 | $428.0K | 0.00% | −371,209−36.4% | Reduced |
| Vanguard Group Inc | 728,484 | $480.8K | 0.00% | 00.0% | Unchanged |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 1,038,296 | $685.3K | 2.29% | 00.0% | Unchanged |
| Glenview Capital Management, LLC | 1,200,788 | $792.5K | 0.02% | −117,500−8.9% | Reduced |
| Kennedy Lewis Management LP | 4,939,931 | $3.26M | 14.06% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 8,434,560 | $5.57M | 0.61% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −18,639−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,880−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −157−100.0% | Sold out |